Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Roy Maute_2024
VIEWPOINTS

Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots

Shots:  Recently Pheast Therapeutics shared the preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor at the 20th Annual PEGS Boston Summit  Today, at PharmaShots, we had a dialogue exchange with Roy Maute, Cofounder and CEO of Pheast Therapeutics  Pheast Therapeutics currently plans to initiate a clinical trial in H1’25  Saurabh: Can you walk me…
June 26, 2024

Read more

New Drug Designations - May 2024
INSIGHTS+

New Drug Designations – May 2024

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 12 small molecules, 7 biologics, 9 cell & gene therapies, 1 vaccine, 1 peptide, 1 RNA candidate, 1 recombinant fusion protein, 1 imaging agent and 6 devices  This…
June 25, 2024

Read more

VIEWPOINTS_Moitreyee Chatterjee-Kishore1_Kohei Shitara2_2024
VIEWPOINTS

Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots

Shots:  East Asia and East Europe report significant incidences of Gastric Cancer. In 2022, Japan registered around 44,000 mortalities due to Gastric Cancer  VYLOY, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, received Japan’s approval in combination with chemotherapy for patients with HER2 -ve, CLDN18.2+ve, unresectable, advanced, or recurrent gastric cancer  Today, at PharmaShots we have Moitreyee…
June 24, 2024

Read more

VIEWPOINTS_Lev Becker_2024
VIEWPOINTS

Onchilles Pharma at AACR 2024: Lev Becker in a Stimulating Conversation with PharmaShots

Shots:  Recently, Onchilles Pharma unveiled findings from the late-stage preclinical data of its two candidates: N17350 and N17465  Today at PharmaShots, we had an engaging dialogue exchange with Lev Becker, Associate Professor, University of Chicago and Cofounder, Onchilles Pharma  Lev highlights the unique novel mechanism that Onchilles Pharma leverages to treat a wide range of…
June 19, 2024

Read more

VIEWPOINTS_Kari Wong1_Emma Tallantyre2_2024
VIEWPOINTS

Enhancing Multiple Sclerosis Research: Dr. Kari Wong and Dr. Emma Tallantyre in Conversation with PharmaShots

Shots:  Multiple Sclerosis affects over 2.8M people globally. Despite several tech infusions in MS research, the exact cause of the condition remains unknown  Recently, Metabolon, known for providing metabolomics solutions joined hands with the Division of Psychological Medicine and Clinical Neuroscience (DPMCN) at Cardiff University to discover new biomarkers to expedite the understanding and treatment…
June 17, 2024

Read more

PharmaShots Magazine - June 2024 Edition
MAGAZINE

PharmaShots Magazine – June 2024 Edition

May had been a busy month for PharmaShots with an unceasing influx of life science updates.   In our most-read Top 20 section, we published reports on Diagnostic Companies and Medical Device Companies.  Like every month, PharmaShots published reports on Key Biosimilars Events, FDA approvals, and EMA approvals along with the New Drug Designation Report. In the Disease of the Month report, we explored Sjögren’s…
June 13, 2024

Read more

INSIGHTS+

Disease of the Month – Fabry Disease

Shots:  Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components  In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…
June 12, 2024

Read more

VIEWPOINTS_Patrick Mooney_2024
VIEWPOINTS

Intraocular Drug Delivery: Patrick Mooney from SpyGlass Pharma in Conversation with PharmaShots

Shots:  Out of the 5M cataract procedures in the US, around one-fifth are conducted on patients with glaucoma or ocular hypertension. There’s an unmet need for drug delivery for patients who struggle with topical drops  Today, with PharmaShots, CEO of SpyGlass Pharma, Patrick Mooney, sharing insights from the data presented at the ASCRS Annual Meeting  Patrick…
June 10, 2024

Read more

Load more